Published in final edited form as:

J Clin Psychiatry. ; 80(4): . doi:10.4088/JCP.18m12422.

High Prevalence of Metabolic Syndrome among Adolescents and Young Adults with Bipolar Disorder

Christine Li, MD^{a,b}, Boris Birmaher, MD^c, Brian Rooks, PhD^c, Mary Kay Gill, MSN, JD^c, Heather Hower, MSW^d, David A. Axelson, MD^e, Daniel P. Dickstein, MD^{d,f}, Tina R. Goldstein, PhD^c, Fangzi Liao, MS^c, Shirley Yen, PhD^{d,g}, Jeffrey Hunt, MD^{d,f}, Satish Iyengar, PhD^h, Neal D. Ryan, MD^c, Michael A. Strober, PhDⁱ, Martin B. Keller, MD^g, Benjamin I. Goldstein, MD, PhD^{a,b}

^aCentre for Youth Bipolar Disorder, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada

^bUniversity of Toronto Faculty of Medicine, Toronto, Ontario, Canada

^cDepartment of Psychiatry, Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

^dDepartment of Psychiatry and Human Behavior, Warren Alpert Medical School of Brown University, Box G-BH, Providence, RI, USA.

^eDepartment of Psychiatry, Nationwide Children's Hospital and The Ohio State College of Medicine, Columbus, OH, USA.

^fBradley Hospital, Riverside, RI, USA

^gButler Hospital, Riverside, RI, USA.

^hDepartment of Statistics, University of Pittsburgh, Pittsburgh, PA, USA.

ⁱDepartment of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA.

Abstract

Objective: Despite abundant literature demonstrating increased metabolic syndrome (MetS) prevalence and important clinical correlates of MetS among middle-age adults with bipolar disorder (BD), little is known about this topic among adolescents and young adults early in their course of BD. We therefore examined this topic in the Course and Outcome of Bipolar Youth (COBY) study.

Methods: Cross-sectional, retrospective study of 162 adolescents and young adults (20.8 ± 3.7 years; range = 13.6 to 28.3) with BD (I, II, or not otherwise specified, based on DSM-IV) enrolled in COBY between 2000 and 2006. MetS measures (blood pressure, glucose, high-density lipoproteins, triglycerides, and waist circumference), defined using the International Diabetes Federation (IDF) criteria, were obtained at a single time-point. Mood, comorbidity and treatment

over the 6 months preceding the MetS assessment were evaluated using the Longitudinal Interval Follow-up Evaluation (LIFE).

Results: The prevalence of MetS in the sample was 19.8% (32/162). Low HDL (56.5%) and abdominal obesity (46.9%) were the most common MetS criteria. MetS was nominally associated with lower lifetime global functioning at COBY intake (OR=0.97, $p=0.06$). MetS was significantly associated with percentage of weeks in full-threshold pure depression (OR=1.07, $p=0.02$), and percentage of weeks receiving antidepressant medications (OR=1.06, $p=0.001$) in the preceding 6 months. MetS was not associated with manic symptoms or medications other than antidepressants.

Conclusion: The prevalence of MetS in this sample was at least double compared to the general population. Moreover, MetS is associated with increased burden of depression symptoms in this group. Management of early-onset BD should integrate strategies focused on modifying MetS risk factors.

Keywords

bipolar disorder; metabolic syndrome; adolescent; young adult

INTRODUCTION

Bipolar disorder (BD) is a recurrent and severe mood disorder that, in addition to the burden of depressive and manic symptoms, is associated with significant medical and psychiatric comorbidities.¹ Numerous studies have demonstrated a high prevalence of metabolic syndrome (MetS) and MetS components (obesity, dyslipidemia, hypertension, and hyperglycemia) in adults with BD^{2–9}, with MetS prevalence ranging from about 10% to over 60%.^{2, 10} MetS is a cluster of clinical and biochemical abnormalities that predispose individuals to cardiovascular disease (CVD) and diabetes mellitus.¹¹ The International Diabetes Federation (IDF) criteria for MetS require the presence of central obesity (waist circumference > 37 in. for men, > 31.5 in. for women), plus any two of high triglycerides (> 150 mg/dL), low high-density lipoprotein [HDL]-C (< 40 mg/dL for men, < 50 mg/dL for women), high systolic (>130mmHg) and/or diastolic (>85mmHg) blood pressure, and high fasting glucose (> 100mg/dL)¹². A meta-analysis of 81 articles, including 6983 adult participants, found 37.3% prevalence of MetS in BD, an odds ratio of 1.97 vs. the general population, and increased risk of MetS among those currently treated with antipsychotics.¹⁰ Among individual MetS components, abdominal obesity is the most common criterion (48.7%–61% depending on the specific MetS definition), followed by high blood pressure (47.1%), low HDL (42.1%), and high triglycerides (39.3%), with high glucose being the least common (11.4%–173%, depending on the specific MetS definition).

CVD is a leading cause of increased mortality in individuals with BD.¹³ The presence of MetS and its components is associated with increasing age^{4, 14–18} as well as with important clinical characteristics among adults with BD including antipsychotic medications^{19–21}, more psychiatric hospitalizations²², and suicide attempts.²³ Specific MetS components such as obesity have also been linked with proxies for greater BD severity including poorer treatment outcome²⁴, rapid cycling, chronic course²⁵, and lower functioning.^{22, 25} Although most clinical studies include patients taking medications with known propensity for MetS

criteria (e.g. antipsychotics, lithium, divalproex), particularly obesity, epidemiologic studies that include BD samples with low rates of antimanic medication use have also reported increased rates of obesity in BD.^{26, 27}

Despite the substantial number of studies investigating MetS in adults with BD², little is known about MetS among adolescents and young adults with BD. One study of 200 Italian adults with BD included 22 subjects between the ages of 18 and 30 years. The prevalence of MetS was 9.1% in this age group, and the rate increased linearly with age.²⁸ This value is higher than the MetS prevalence of 4.2% in the general pediatric and adolescent population in Southern Italy.²⁹ Other studies have investigated specific components of MetS^{30–33} or focused on the effects of antipsychotics on dimensional levels of MetS criteria (e.g. changes in triglyceride levels) among youth with BD.^{34, 35} For example, a study of 1841 pediatric BD patients found that the BD cohort had increased rates of obesity and diabetes mellitus compared to healthy controls and these higher rates are associated with more outpatient service use.³¹ Data from the Course and Outcome of Bipolar Illness in Youth (COBY) study revealed a 42% prevalence of overweight and obesity among pediatric BD subjects compared to 34% among the general youth population.³⁰ Being overweight or obese was found to be most robustly associated with younger age, non-white race, lifetime physical abuse, substance use disorders, psychiatric hospitalizations, and exposure to 2 medication classes associated with weight gain.³⁰ Another study of 1848 BD subjects in Taiwan reported higher prevalence and incidence of hypertension in young adults with BD compared to the general population.³³

Considering the findings of increased MetS prevalence and important clinical correlates of MetS among primarily middle-aged adults with BD, additional studies on MetS among youth and young adults with BD are indicated. The only prior study regarding MetS in this age range had a small number of subjects (N=22)²⁸, precluding an examination of clinical correlates. MetS confers significant risk for CVD and the risk ratio for CVD mortality in BD compared to the general population is highest among young adults.^{36, 37} For example, a study examining CVD mortality in Sweden reported that the CVD mortality rate ratios among BD patients between 25 – 34 years old is about 8, compared to 2 to 4 among older BD patients.³⁶ Indeed, BD among adolescents was recently highlighted by the American Heart Association as a moderate-risk condition associated with accelerated atherosclerosis and early CVD.³⁸ We therefore examined the prevalence of MetS and its components, as well as their clinical correlates, in a relatively large sample of adolescents and young adults with BD enrolled in the COBY study. We hypothesized that the prevalence of MetS in COBY would be greater than the general population, and that MetS would be associated with exposure to antimanic medications, greater mood symptom burden, higher rates of suicide attempts and hospitalizations, and lower global functioning.

METHODS

Metabolic Syndrome

Metabolic syndrome was defined using the International Diabetes Federation (IDF) criteria³⁹, requiring the presence of central obesity (waist circumference > 37 in. for men, > 31.5 in. for women), plus any two of high triglycerides (≥ 150 mg/dL), low HDL-C (< 40

mg/dL for men, < 50 mg/dL for women), high systolic (>130mmHg) and/or diastolic (>85mmHg) blood pressure, and high fasting glucose (≥100mg/dL). Waist circumference was measured with a SECA 201 girth measuring tape according to IDF guidelines.⁴⁰ For subjects under the age of 16, waist circumference percentile values from IDF were used.³⁹ Blood was drawn from each subject between 9:00am-12:00pm after a 10-hour fast, and sent to the local hospital laboratory for analysis of glucose and lipids levels. Systolic and diastolic blood pressure was measured twice using Life Source automated blood pressure monitors, with analyses examining the mean measurements.

Participants

The methods for COBY have been described in detail elsewhere.^{41–43} In short, the study involved youths ages 7 to 17 years 11 months at intake, with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) BD-I or -II or operationally defined BD not otherwise specified (NOS). Participants in the present cross-sectional, retrospective analysis included 162 adolescents and young adults, mean age 20.8 ± 3.7 years, 40.7% females, 81.5% white race (similar to 45.5% females and 82.6% white race in the overall COBY sample), enrolled in COBY with BD-I (69.1%), -II (14.8%), or -NOS (16%). Consecutive participants contacted for follow-up visits as part of the overall COBY study at the Pittsburgh and Brown sites were invited to participate. Participants completed a MetS visit 8.52 ± 1.60 years after enrollment in COBY. Participants are being followed prospectively, and future longitudinal studies will be forthcoming. Exclusion criteria were: infectious illness within 14 days, known inflammatory or auto-immune illness, use of steroidal medication or insulin within one month of the MetS visit, self-reported alcohol or illicit drug use within 24-hours, and pregnancy.

Procedures

Each participating university's institutional review board approved the study. At enrollment, participants and parents gave informed consent and were directly interviewed for the presence of current and lifetime psychiatric illnesses in the youths.

Psychiatric and Anthropometric Measures

Psychiatric diagnoses were validated with the Schedule for Affective Disorders and Schizophrenia for School-Age Children—Present and Lifetime Version (K-SADS-PL),⁴⁴ the Kiddie Mania Rating Scale (K-MRS),⁴⁵ and the depression section of the K-SADS-P.⁴⁶ Psychiatric symptoms over the 6-month period preceding the MetS visit were evaluated using the Longitudinal Interval Follow-Up Evaluation (LIFE)⁴⁷ and tracked on a week-by-week basis using this instrument's Psychiatric Status Rating (PSR) scales. Analyses focused on PSR scores over the 6 months prior to the measurement of MetS components, as this was the target interval between COBY visits and associations between MetS and its predictors were anticipated to be strongest when examining the most proximal epoch of follow-up.

All assessments were performed by research staff trained to reliably administer the interviews. Interview results were presented to child psychiatrists or psychologists, who confirmed the diagnoses and PSR scores. Kappa values for psychiatric disorders on the K-

SADS were 0.8, and intraclass correlation coefficients for syndromal/subsyndromal mood symptoms via the PSR were 0.75.

First and second degree family psychiatric history was ascertained using the Family History Screen.⁴⁸ Socioeconomic status was ascertained at intake using the four-factor Hollingshead scale.⁴⁹ Abuse was ascertained using the KSADS-PL. Current and lifetime pharmacological treatment exposure were obtained at the intake assessment. In addition, the Psychotropic Treatment Record and the Psychosocial Treatment Schedule of the LIFE were used to ascertain treatment exposure in the preceding 6-month period on a week-by-week basis. Weekly exposure was dichotomized (yes/no) for any psychotropic medication and for each of the following: antimanic anticonvulsants (i.e. carbamazepine and/or divalproex sodium), lithium, second-generation antipsychotics, antidepressants, and stimulants. Weekly exposure to psychosocial treatments was likewise examined for three categories of intensity: inpatient hospitalization/residential treatment, specialized intensive services, and standard outpatient services. Global functioning was assessed at intake using the Children's Global Assessment Scale (C-GAS).⁵⁰

Statistical Analyses

Statistical analyses were performed using SAS (9.3) software. Correlations among the MetS components were examined with Pearson correlation coefficients. Comparisons of demographic and lifetime clinical characteristics by MetS group were performed using parametric and non-parametric tests where appropriate.

Logistic regression models were used to analyze the associations between presence of MetS and prospective course variables collected during the 6 months preceding blood draw. The percent of weeks with sub- and full-threshold criteria for depression, mania/hypomania, and comorbid conditions were converted to number of weeks with sub- and full-threshold criteria, respectively, giving an associated odds ratio which reflects the expected percent increase in odds of having MetS for an additional week of symptoms. Demographic and/or lifetime clinical measures that exhibited significant associations with presence of MetS at the $p = 0.10$ level were included in multiple logistic regression models as potential confounders. Given the hypothesis-generating (i.e., exploratory) nature of the current study, we did not correct for multiple comparisons.

RESULTS

The overall prevalence of MetS in the sample was 19.8% (32/162). The prevalence of each MetS criteria were as follows: low HDL-C: 56.5%; abdominal obesity: 46.9%; high blood pressure: 24.2%, high triglycerides: 15.4%; and high glucose: 15.4%. The proportion of participants with varying counts of MetS components was as follows: 21.3% for 0 MetS components, 30% for 1 component, 28.1% for 2 components, and 20.6% for 3+ components; 78.8% of participants had at least one MetS component, while 48.8% had at least two. The mean waist circumference was 35.3 inches (SD=5.6, range=23.8–56.8). The mean systolic blood pressure was 115.30 mmHg (SD=10.67, range=90.0–142.5), and mean diastolic blood pressure was 77.09 mmHg (SD=9.54, range=47.5–104.5). The mean triglycerides was 100.68 mg/dL (SD=79.4, range=25.0–636.0). The mean glucose was

93.17mg/dL (SD=14.93, range=56.0–239.0). The mean HDL was 47.56 mg/dL (SD=15.95, range = 21.0–101.0). We examined the co-occurrence of MetS components pairwise among participants with MetS. The most common co-occurrences were central obesity with low HDL (96.8%), central obesity with high diastolic blood pressure (51.6%), and low HDL with high diastolic blood pressure (50%).

For comparative reasons, we also examined MetS using the NCEP definitions. The NCEP criteria are identical to the IDF criteria, except abdominal obesity is defined as waist circumference >40 inches for men and >35 inches for women, and MetS requires any 3 of central obesity, high triglycerides, low HDL-C, high systolic and/or diastolic blood pressure, and high fasting glucose.⁵¹ Using the NCEP criteria, the prevalence of MetS is 16.1% (26/162), compared to 19.8% using the IDF criteria. The prevalence of MetS components using the NCEP criteria are identical to those using IDF criteria, except the prevalence of abdominal obesity (30.4%) is lower than that of IDF criteria (46.9%).

Table 1 presents the demographic, clinical, and family psychiatric history correlates of MetS. There was only a non-significant association (OR=0.97, $p=0.06$) between most severe lifetime C-GAS rating at intake and presence of MetS; this variable was therefore included as a covariate for subsequent analyses. We also evaluated in exploratory fashion whether atypical depression symptoms were associated with MetS. Because the PSR scale does not rate the severity of individual symptoms, we addressed this topic based on the presence of the following atypical depression symptoms from the K-SADS-P depression section at intake: increased sleep, fatigue, increased weight and/or appetite. Participants with, as compared to without, MetS were nominally more likely to have had increased sleep (28.1% vs. 12.4%, $p=0.05$), and nominally more likely to have all three of the atypical depression symptoms (12.5% vs. 3.1%, $p=0.05$).

Table 2 presents the association between predictors of MetS in the 6 months preceding assessment of MetS. Presence of MetS was significantly associated with percent weeks in any full-threshold mood state (OR=1.05, $p=0.04$, CI=(1,1.10)), % weeks in full-threshold pure depression (OR=1.07, $p=0.02$, CI=(1.01,1.13)), and percent weeks receiving antidepressant medications (OR=1.06, $p=0.001$, CI=(1.02,1.10)) in univariate analyses. Only the associations with depression symptoms and antidepressants remained significant after controlling for most severe lifetime C-GAS at intake.

DISCUSSION

To our knowledge, this is the first study to focus on MetS among adolescents and young adults with BD. The overall prevalence of MetS, using IDF criteria, in the current study sample was 19.8%. Abdominal obesity and low HDL were the most common, whereas high triglycerides and elevated glucose were the least common criteria. MetS was significantly associated with most severe lifetime C-GAS rating at intake. Contrary to hypotheses, antimanic medications, and second-generation antipsychotics specifically, were not significantly associated with MetS. Whereas, the burden of overall depression symptoms and of any full-threshold mood state over the preceding 6 months was greater, as was use of antidepressant medications, among participants with MetS. The prevalence of MetS in this

sample was higher than the prevalence of 9.1% found among 22 young adults with BD in an Italian sample.²⁸ In contrast, the prevalence of MetS in this study was lower than those found in most adult BD samples, in which the prevalence of MetS can exceed 60% (defined using various criteria).^{2, 10} This finding is expected as MetS is generally less prevalent in youth and increases with age.^{28, 52} By comparison to the current sample, the prevalence of IDF-define MetS among adolescents in the general U.S. population is 5.5%.⁵³

The study has three primary limitations that should be considered before interpreting the findings. First, this study is based on a single measurement of MetS components, which precludes conclusions regarding causality and/or direction of the observed associations. Repeated-measures analyses will be informative in better understanding the associations between MetS and mood symptoms in BD. Second, the study did not include a healthy and/or clinical control group. Thus, it is not clear whether or not the associations observed in the current study are specific to BD. However, it is important to note the prevalence of MetS in the current study is substantially higher than that reported in the comparably-aged general population. Third, the study is based on a clinical sample, and may not be representative of untreated adolescents and young adults with BD.

The prevalence of hypertriglyceridemia (15.4%) among BD participants was similar to U.S. adolescents in the general population (14.2%). BD participants had increased prevalence of abdominal obesity (46.9% vs. 34.7%), low HDL-C (56.5% vs. 21.6%), high blood pressure (24.2% vs. 4.1%), and high glucose (15.4% vs. 11.8%) compared to U.S. adolescents in the general population.⁵³ In addition, there was greater proportion of participants with 3+ MetS components among BD adolescents (13.6% vs. 5.5%), whereas the proportion with 2+ MetS components was similar (24.7% vs. 21.3%).

We found that the burden of depression and any full-threshold mood state symptoms in the preceding 6 months was greater among participants with MetS. Previous studies have reported associations between depression and higher prevalence of MetS.⁵⁴ Putative links between mood symptoms and MetS include the direct effect of those symptoms (e.g. sleep disturbance, sedentary lifestyle, increased appetite), the effects of treatments targeting those symptoms (as described below), and shared biological mechanisms such as inflammation. Indeed, a recent study regarding inflammation based on the COBY sample found that several MetS components were associated with increased levels of pro-inflammatory markers.⁴³

Although antidepressants have been associated with weight gain, there is less evidence that modern antidepressants confer meaningfully increased risk of MetS.^{55–58} The maximum severity of depression symptoms in the preceding 6 months was not associated with MetS; however, it remains possible that this latter association is confounded by indication, whereby participants with more severe depression were more likely to receive antidepressant treatment. Indeed, among young adult women, history of major depression is associated with a two-fold risk of MetS, independent of demographic characteristics, smoking, physical activity, nutrition, and alcohol use.⁵⁹ Similar associations are observed for self-reported depression symptoms⁶⁰. Another recent study found that presence of major depression with anhedonia in a community sample of young adults is associated with increased prevalence of

MetS, whereas this was not the case for major depression without anhedonia⁶¹. Future studies are warranted to evaluate for sex differences and for specific symptom-related differences in terms of the link between MetS and depression in youth and young adults.

In contrast to contemporary antidepressants, antimanic medications in general, and second-generation antipsychotics in particular, are consistently associated with increased prevalence of MetS and its components in adults with BD.^{2, 10} We previously reported that overweight/obesity among COBY participants at intake was associated with lifetime use of second-generation antipsychotics in univariate but not multivariate analyses.³⁰ One may speculate that there are developmental differences in terms of risk factors for MetS in BD; for example, the impact of psychiatric symptoms and shared biology on MetS may be greater in youth whereas the impact of psychiatric medications on MetS is greater in adults. Replication studies are warranted to evaluate this and other putative explanations for the lack of association between antimanic medications and MetS. Similarly, although we did not replicate previous studies that demonstrated associations between MetS and psychiatric hospitalization²³ and suicide attempts^{3, 62}, present findings were in the same direction, with numerically greater prevalence of MetS among COBY participants with lifetime history of psychiatric hospitalization (OR=1.50, $p=0.35$), and suicide attempt (OR=1.71, $p=0.18$).

In summary, this is the first study to examine the prevalence of MetS and its components, as well as their clinical correlates, in a relatively large sample of adolescents and young adults with BD. This study revealed that the prevalence of MetS among youth with BD is roughly quadruple that of the general population, and that MetS is associated with increased burden of depression symptoms. Although results in the current study require replication in other samples with a direct comparison group, our findings suggest that excessive rates of MetS and its components, which are risk factors for CVD and diabetes, are already apparent among adolescents and young adults with BD. This phenomenon calls for the need to implement early screening, prevention, and intervention strategies for MetS and its components. Management of BD should ideally integrate medical and psychiatric care with attention on modifying MetS risk factors.^{63–65} Finally, the possibility that reducing MetS can reduce the burden of depression in BD remains, and studies addressing this topic are warranted.

Acknowledgements

This research was supported by the National Institute of Mental Health (NIMH) Course and Outcome of Bipolar Youth (COBY) study grants MH059929 (B.B.), MH59691 (M.B.K./S.Y.), and MH59977 (M.S.). The authors thank the study participants and families for their participation, the COBY research team, and NIMH for their support.

Sources of financial and material support: This research was supported by the National Institute of Mental Health (NIMH) Course and Outcome of Bipolar Youth (COBY) study grants MH059929 (B.B.), MH59691 (M.B.K./S.Y.), and MH59977 (M.S.). No funding agency provided direct support in the conduct and/or publication of the study.

Disclosures of Interests

Dr. Axelson has served as a consultant for Janssen Research and received royalties from UpToDate. Dr. Birmaher receives or will receive royalties for publications from Random House, Inc. (New Hope for Children and Teens with Bipolar Disorder), Lippincott Williams & Wilkins (Treating Child and Adolescent Depression), and UpToDate. He is employed by the University of Pittsburgh and the University of Pittsburgh Medical Center/Western Psychiatric Institute and Clinic and receives research funding from NIMH.

Dr. Dickstein received grant support from NIMH, and an independent investigator grant from the Brain and Behavior Research Foundation (NARSAD). Ms. Gill receives grant support from NIMH. Dr. B. Goldstein received grant or research support from the Brain and Behavior Research Foundation (NARSAD), Brain Canada, the Canadian Institutes of Health Research, the Heart and Stroke Foundation, NIMH, the Ontario Ministry of Research and Innovation, and University of Toronto Department of Psychiatry. Dr. T. Goldstein receives grant support from NIMH, the American Foundation for Suicide Prevention (AFSP), and the Brain & Behavior Research Foundation, and royalties from Guilford Press. Ms. Hower receives grant support from NIMH. Dr. Hunt receives grant support from NIMH, and receives honoraria from Wiley Publishers as a Senior Editor of the *Brown University Child and Adolescent Psychopharmacology Update*. Drs. Iyengar, Keller, and Liao and Mr. Rooks receive grant support from NIMH. Dr. Ryan received grant or research support from NIMH. He served on the Scientific Advisory Board of the Child Mind Institute. Dr. Strober receives grant support from NIMH, and support from the Resnick Endowed Chair in Eating Disorders at UCLA. Dr. Yen receives grant support from NIMH and American Foundation for Suicide Prevention, and is a consultant at Janssen Research and Development, LLC.

REFERENCES

1. Weber NS, Fisher JA, Cowan DN, Niebuhr DW Psychiatric and General Medical Conditions Comorbid With Bipolar Disorder in the National Hospital Discharge Survey. *Psychiatric Services* 2011;62(10):1152–1158. [PubMed: 21969641]
2. McElroy SL, Keck PE Jr Metabolic syndrome in bipolar disorder: a review with a focus on bipolar depression. *The Journal of clinical psychiatry* 2014 1;75(1):46–61. [PubMed: 24502861]
3. McIntyre RS, Danilewitz M, Liauw SS, et al. Bipolar disorder and metabolic syndrome: an international perspective. *Journal of affective disorders* 2010 11;126(3):366–387. [PubMed: 20541810]
4. Sicras A, Rejas J, Navarro R, Serrat J, Blanca M Metabolic syndrome in bipolar disorder: a cross-sectional assessment of a Health Management Organization database. *Bipolar disorders* 2008 7;10(5):607–616. [PubMed: 18657245]
5. Guan N, Liu H, Diao F, Zhang J, Zhang M, Wu T Prevalence of metabolic syndrome in bipolar patients initiating acute-phase treatment: a 6-month follow up. *Psychiatry and clinical neurosciences* 2010 12;64(6):625–633. [PubMed: 21105953]
6. Elmslie JL, Porter RJ, Joyce PR, Hunt PJ, Shand BI, Scott RS Comparison of insulin resistance, metabolic syndrome and adiponectin in overweight bipolar patients taking sodium valproate and controls. *The Australian and New Zealand journal of psychiatry* 2009 1;43(1):53–60. [PubMed: 19085528]
7. Lee NY, Kim SH, Cho B, et al. Patients taking medications for bipolar disorder are more prone to metabolic syndrome than Korea's general population. *Progress in neuro-psychopharmacology & biological psychiatry* 2010 10 1;34(7):1243–1249. [PubMed: 20599461]
8. Bly MJ, Taylor SF, Dalack G, et al. Metabolic syndrome in bipolar disorder and schizophrenia: dietary and lifestyle factors compared to the general population. *Bipolar disorders* 2014 5;16(3):277–288. [PubMed: 24330321]
9. Silarova B, Giltay EJ, Van Reedt Dortland A, et al. Metabolic syndrome in patients with bipolar disorder: comparison with major depressive disorder and non-psychiatric controls. *Journal of psychosomatic research* 2015 4;78(4):391–398. [PubMed: 25742722]
10. Vancampfort D, Vansteelandt K, Correll CU, et al. Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators. *The American journal of psychiatry* 2013 3;170(3):265–274. [PubMed: 23361837]
11. Miranda PJ, DeFronzo RA, Califf RM, Guyton JR Metabolic syndrome: definition, pathophysiology, and mechanisms. *American heart journal* 2005 1;149(1):33–45. [PubMed: 15660032]
12. Paul ZMM AKG, Francine K, et al. The metabolic syndrome in children and adolescents – an IDF consensus report. *Pediatric Diabetes* 2007;8(5):299–306. [PubMed: 17850473]
13. Roshanaei-Moghaddam B, Katon W Premature mortality from general medical illnesses among persons with bipolar disorder: a review. *Psychiatric services (Washington, DC)* 2009 2;60(2):147–156.
14. Cardenas J, Frye MA, Marusak SL, et al. Modal subcomponents of metabolic syndrome in patients with bipolar disorder. *Journal of affective disorders* 2008 2;106(1–2):91–97. [PubMed: 17628693]

15. Godin O, Etain B, Henry C, et al. Metabolic syndrome in a French cohort of patients with bipolar disorder: results from the FACE-BD cohort. *The Journal of clinical psychiatry* 2014 10;75(10): 1078–1085; quiz 1085. [PubMed: 25373115]
16. Grover S, Aggarwal M, Chakrabarti S, et al. Prevalence of metabolic syndrome in bipolar disorder: an exploratory study from North India. *Progress in neuro-psychopharmacology & biological psychiatry* 2012 1 10;36(1):141–146. [PubMed: 22056292]
17. Maina G, D'Ambrosio V, Aguglia A, Paschetta E, Salvi V, Bogetto F [Bipolar disorders and metabolic syndrome: a clinical study in 185 patients]. *Rivista di psichiatria* 2010 1-2;45(1):34–40. [PubMed: 20380240]
18. Salvi V, D'Ambrosio V, Bogetto F, Maina G Metabolic syndrome in Italian patients with bipolar disorder: a 2-year follow-up study. *Journal of affective disorders* 2012 2;136(3):599–603. [PubMed: 22119084]
19. Yumru M, Savas HA, Kurt E, et al. Atypical antipsychotics related metabolic syndrome in bipolar patients. *Journal of affective disorders* 2007 3;98(3):247–252. [PubMed: 16970993]
20. Fiedorowicz JG, Palagummi NM, Forman-Hoffman VL, Miller DD, Haynes WG Elevated prevalence of obesity, metabolic syndrome, and cardiovascular risk factors in bipolar disorder. *Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists* 2008 7-9;20(3):131–137. [PubMed: 18633739]
21. Chang HH, Chou CH, Chen PS, et al. High prevalence of metabolic disturbances in patients with bipolar disorder in Taiwan. *Journal of affective disorders* 2009 9;117(1–2):124–129. [PubMed: 19193445]
22. McIntyre RS, Woldeyohannes HO, Soczynska JK, et al. The rate of metabolic syndrome in euthymic Canadian individuals with bipolar I/II disorder. *Advances in therapy* 2010 11;27(11): 828–836. [PubMed: 20878373]
23. Fagiolini A, Frank E, Scott JA, Turkin S, Kupfer DJ Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians. *Bipolar disorders* 2005 10;7(5): 424–430. [PubMed: 16176435]
24. Kemp DE, Gao K, Chan PK, Ganocy SJ, Findling RL, Calabrese JR Medical comorbidity in bipolar disorder: relationship between illnesses of the endocrine/metabolic system and treatment outcome. *Bipolar disorders* 2010 6;12(4):404–413. [PubMed: 20636638]
25. Ruzickova M, Slaney C, Garnham J, Alda M Clinical features of bipolar disorder with and without comorbid diabetes mellitus. *Canadian journal of psychiatry Revue canadienne de psychiatrie* 2003 8;48(7):458–461. [PubMed: 12971015]
26. Goldstein BI, Liu SM, Zivkovic N, Schaffer A, Chien LC, Blanco C The burden of obesity among adults with bipolar disorder in the United States. *Bipolar disorders* 2011 6;13(4):387–395. [PubMed: 21843278]
27. McIntyre RS, Konarski JZ, Wilkins K, Soczynska JK, Kennedy SH Obesity in bipolar disorder and major depressive disorder: results from a national community health survey on mental health and well-being. *Canadian journal of psychiatry Revue canadienne de psychiatrie* 2006 4;51(5):274–280. [PubMed: 16986816]
28. Salvi V, D'Ambrosio V, Rosso G, Bogetto F, Maina G Age-specific prevalence of metabolic syndrome in Italian patients with bipolar disorder. *Psychiatry and clinical neurosciences* 2011 2;65(1):47–54. [PubMed: 21265935]
29. Martino F, Puddu PE, Pannarale G, et al. Metabolic syndrome among children and adolescents from Southern Italy: contribution from the Calabrian Sierras Community Study (CSCS). *International journal of cardiology* 2014 12 15;177(2):455–460. [PubMed: 25443246]
30. Goldstein BI, Birmaher B, Axelson DA, et al. Preliminary findings regarding overweight and obesity in pediatric bipolar disorder. *The Journal of clinical psychiatry* 2008 12;69(12):1953–1959. [PubMed: 19026266]
31. Jerrell JM, McIntyre RS, Tripathi A A cohort study of the prevalence and impact of comorbid medical conditions in pediatric bipolar disorder. *The Journal of clinical psychiatry* 2010 11;71(11): 1518–1525. [PubMed: 20584522]

32. Chien IC, Chang KC, Lin CH, Chou YJ, Chou P Prevalence of diabetes in patients with bipolar disorder in Taiwan: a population-based national health insurance study. *General hospital psychiatry* 2010 11-12;32(6):577–582. [PubMed: 21112448]
33. Chien IC, Lin CH, Chou YJ, Chou P Risk of hypertension in patients with bipolar disorder in Taiwan: a population-based study. *Comprehensive psychiatry* 2013 8;54(6):687–693. [PubMed: 23433221]
34. McIntyre RS, Jerrell JM Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents. *Archives of pediatrics & adolescent medicine* 2008 10;162(10):929–935. [PubMed: 18838645]
35. Moreno C, Merchan-Naranjo J, Alvarez M, et al. Metabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses. *Bipolar disorders* 2010 3;12(2):172–184. [PubMed: 20402710]
36. Westman J, Hallgren J, Wahlbeck K, Erlinge D, Alfredsson L, Osby U Cardiovascular mortality in bipolar disorder: a population-based cohort study in Sweden. *BMJ open* 2013;3(4).
37. Osby U, Brandt L, Correia N, Ekblom A, Sparen P Excess mortality in bipolar and unipolar disorder in Sweden. *Archives of general psychiatry* 2001 9;58(9):844–850. [PubMed: 11545667]
38. Goldstein BI, Carnethon MR, Matthews KA, et al. Major Depressive Disorder and Bipolar Disorder Predispose Youth to Accelerated Atherosclerosis and Early Cardiovascular Disease: A Scientific Statement From the American Heart Association. *Circulation* 2015 9 8;132(10):965–986. [PubMed: 26260736]
39. Federation ID IDF consensus definition of metabolic syndrome in children and adolescents. 2007.
40. International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. *IDF Consens Worldw Defin Metab Syndr* 2006;28:1–7.
41. Birmaher B, Axelson D, Strober M, et al. Clinical course of children and adolescents with bipolar spectrum disorders. *Archives of general psychiatry* 2006 2;63(2):175–183. [PubMed: 16461861]
42. Birmaher B, Axelson D, Goldstein B, et al. Four-year longitudinal course of children and adolescents with bipolar spectrum disorders: the Course and Outcome of Bipolar Youth (COBY) study. *The American journal of psychiatry* 2009 7;166(7):795–804. [PubMed: 19448190]
43. Goldstein BI, Lotrich F, Axelson DA, et al. Inflammatory markers among adolescents and young adults with bipolar spectrum disorders. *The Journal of clinical psychiatry* 2015 11;76(11):1556–1563. [PubMed: 26646032]
44. Kaufman J, Birmaher B, Brent D, et al. Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. *Journal of the American Academy of Child and Adolescent Psychiatry* 1997 7;36(7):980–988. [PubMed: 9204677]
45. Axelson D, Birmaher BJ, Brent D, et al. A preliminary study of the Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children mania rating scale for children and adolescents. *Journal of child and adolescent psychopharmacology* 2003 Winter;13(4):463–470. [PubMed: 14977459]
46. Chambers WJ, Puig-Antich J, Hirsch M, et al. The assessment of affective disorders in children and adolescents by semistructured interview. Test-retest reliability of the schedule for affective disorders and schizophrenia for school-age children, present episode version. *Archives of general psychiatry* 1985 7;42(7):696–702. [PubMed: 4015311]
47. Keller MB, Lavori PW, Friedman B, et al. The Longitudinal Interval Follow-up Evaluation. A comprehensive method for assessing outcome in prospective longitudinal studies. *Archives of general psychiatry* 1987 6;44(6):540–548. [PubMed: 3579500]
48. Weissman MM, Wickramaratne P, Adams P, Wolk S, Verdelli H, Olfson M Brief screening for family psychiatric history: the family history screen. *Archives of general psychiatry* 2000 Jul; 57(7):675–682.
49. Hollingshead AA Four factor index of social status. *Yale J Sociol* 1975;8:21–52.
50. Shaffer D, Gould MS, Brasic J, et al. A children's global assessment scale (CGAS). *Archives of general psychiatry* 1983 11;40(11):1228–1231. [PubMed: 6639293]
51. National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the

National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation*. 2002/12/18 ed; 2002: 3143–3421.

52. Ford ES, Li C, Zhao G, Pearson WS, Mokdad AH Prevalence of the metabolic syndrome among U.S. adolescents using the definition from the International Diabetes Federation. *Diabetes care* 2008 31(3):587–589. [PubMed: 18071007]
53. Park J, Hilmers DC, Mendoza JA, Stuff JE, Liu Y, Nicklas TA Prevalence of metabolic syndrome and obesity in adolescents aged 12 to 19 years: comparison between the United States and Korea. *Journal of Korean medical science* 2010 1;25(1):75–82. [PubMed: 20052351]
54. Pan A, Keum NN, Okereke OI, et al. Bidirectional Association Between Depression and Metabolic Syndrome: A systematic review and meta-analysis of epidemiological studies. *Diabetes care* 2012 5;35(5):1171–1180. [PubMed: 22517938]
55. Correll CU Weight gain and metabolic effects of mood stabilizers and antipsychotics in pediatric bipolar disorder: a systematic review and pooled analysis of short-term trials. *Journal of the American Academy of Child and Adolescent Psychiatry* 2007 6;46(6):687–700. [PubMed: 17513981]
56. Jerrell JM, McIntyre RS, Tripathi A Childhood treatment with psychotropic medication and development of comorbid medical conditions in adolescent-onset bipolar disorder. *Human psychopharmacology* 2011 10;26(7):451–459. [PubMed: 21898598]
57. Geller B, Luby JL, Joshi P, et al. A randomized controlled trial of risperidone, lithium, or divalproex sodium for initial treatment of bipolar I disorder, manic or mixed phase, in children and adolescents. *Archives of general psychiatry* 2012 5;69(5):515–528. [PubMed: 22213771]
58. Mansoor B, Rengasamy M, Hilton R, et al. The bidirectional relationship between body mass index and treatment outcome in adolescents with treatment-resistant depression. *Journal of child and adolescent psychopharmacology* 2013 9;23(7):458–467. [PubMed: 24024532]
59. Kinder LS, Carnethon MR, Palaniappan LP, King AC, Fortmann SP Depression and the metabolic syndrome in young adults: findings from the Third National Health and Nutrition Examination Survey. *Psychosomatic Medicine* 2004;66(3):316–322. [PubMed: 15184689]
60. Pulkki-Råback L, Elovainio M, Kivimäki M, et al. Depressive symptoms and the metabolic syndrome in childhood and adulthood: a prospective cohort study. *Health psychology : official journal of the Division of Health Psychology, American Psychological Association* 2009;28(1): 108–116.
61. Moreira FP, Jansen K, Cardoso TdA, et al. Metabolic syndrome, depression and anhedonia among young adults. *Psychiatry Research* 2019 2019/01/01;271:306–310. [PubMed: 30522000]
62. Fagiolini A, Chengappa KN, Soreca I, Chang J Bipolar disorder and the metabolic syndrome: causal factors, psychiatric outcomes and economic burden. *CNS drugs* 2008;22(8):655–669. [PubMed: 18601304]
63. Katon WJ, Lin EH, Von Korff M, et al. Collaborative care for patients with depression and chronic illnesses. *The New England journal of medicine* 2010 12 30;363(27):2611–2620. [PubMed: 21190455]
64. Druss BG, von Esenwein SA, Compton MT, Rask KJ, Zhao L, Parker RM A randomized trial of medical care management for community mental health settings: the Primary Care Access, Referral, and Evaluation (PCARE) study. *The American journal of psychiatry* 2010 2;167(2):151–159. [PubMed: 20008945]
65. Kilbourne AM, Post EP, Nossek A, Drill L, Cooley S, Bauer MS Improving medical and psychiatric outcomes among individuals with bipolar disorder: a randomized controlled trial. *Psychiatric services (Washington, DC)* 2008 7;59(7):760–768. [PubMed: 18586993]

Clinical Points

1. Despite greatly increased cardiovascular risk in bipolar disorder, few studies have examined this topic early in life.
2. There are increased rates of metabolic syndrome, a clustering of cardiovascular risk factors, in adolescents and young adults with bipolar disorder, especially those with more persistent depression.
3. Improvements in cardiovascular health or depression may have reciprocal benefits for patients.

Table 1.

Demographic, Clinical, and Family Psychiatric History Correlates of Metabolic Syndrome among Adolescents and Young Adults with Bipolar Disorder

	MetS Group		Wald Chi-square	Odds Ratio	p-value
	MetS Absent (n=130)	MetS Present (n=32)			
Demographics					
Age	20.67 (3.8)	20.90 (3.7)	0.31		0.76
Race (white)	108 (83.1%)	24 (75%)	1.11		0.29
Sex (female)	53 (40.8%)	13 (40.6%)	0.00		0.99
Lifetime Clinical History					
ADHD	97 (74.6%)	26 (81.3%)	0.61	1.47	0.43
Anxiety	89 (68.5%)	23 (71.9%)	0.14	1.18	0.71
Conduct disorder	36 (27.7%)	8 (25%)	0.09	0.87	0.76
Oppositional defiant disorder	76 (58.5%)	22 (68.8%)	1.13	1.56	0.29
Substance use disorder	43 (33.1%)	11 (34.4%)	0.02	1.06	0.89
Psychosis	51 (39.2%)	10 (31.3%)	0.69	0.70	0.40
Psychiatric hospitalization	82 (63.1%)	23 (71.9%)	0.86	1.50	0.35
Suicide attempt	60 (46.2%)	19 (59.4%)	1.77	1.71	0.18
Self-injurious behavior	77 (59.2%)	16 (50%)	0.89	0.69	0.35
Suicidal ideation	104 (80%)	26 (81.3%)	0.03	1.08	0.87
Physical abuse	22 (16.9%)	6 (18.8%)	0.06	1.13	0.81
Sexual abuse	16 (12.3%)	6 (18.8%)	0.89	1.64	0.34
Most severe lifetime C-GAS (at study intake)	39.11 (10.8)	34.80 (12.1)	3.58	0.97	0.06
Family Psychiatric History (1st and 2nd degree)					
Depression	120 (92.3%)	28 (87.5%)	0.74	0.58	0.39
Mania/hypomania	88 (67.7%)	21 (65.6%)	0.05	0.91	0.82
ADHD	71 (54.6%)	17 (53.1%)	0.02	0.94	0.88
Anxiety	103 (79.2%)	23 (71.9%)	0.80	0.67	0.37
Conduct Disorder	50 (38.5%)	14 (43.8%)	0.30	1.24	0.58
Schizophrenia	15 (11.5%)	1 (3.1%)	1.76	0.25	0.18
Substance use disorder	100 (76.9%)	23 (71.9%)	0.36	0.77	0.55
Suicide attempt or completion	64 (49.2%)	18 (56.3%)	0.50	1.33	0.48
Lifetime Psychiatric Medications					
Any psychotropic medication	70 (54.3%)	23 (71.9%)	3.26		0.07
Antimanic anticonvulsants	8 (6.2%)	4 (12.5%)	1.47		0.22
Lithium	13 (10.1%)	5 (15.6%)	0.79		0.37
Second generation antipsychotics	45 (34.6%)	14 (43.8%)	0.93		0.34
Antidepressants	24 (18.6%)	16 (50.0%)	13.53		0.0002
Stimulants	29 (22.5%)	9 (28.1%)	0.45		0.50

Abbreviations: ADHD: attention deficit-hyperactivity disorder; C-GAS: children's global assessment scale MetS: metabolic syndrome

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 2.

Association of Metabolic Syndrome with Psychiatric Symptoms and Treatment in the Preceding Six Months

Psychiatric Symptoms	Odds Ratio ^a	95% Confidence Interval	Unadjusted p-value	Adjusted p-value
Maximum symptom severity in preceding six months				
Depression	1.19	(0.92, 1.53)	0.18	0.35
Mania/Hypomania	0.96	(0.75, 1.24)	0.77	0.85
Psychosis	1.01	(0.95, 1.07)	0.81	0.79
Percentage of weeks with symptoms in preceding six months				
No significant mood symptoms	0.98	(0.95, 1.02)	0.39	0.43
Any sub-threshold mood state	0.98	(0.94, 1.02)	0.34	0.38
Any full-threshold mood state	1.05	(1, 1.10)	0.04	0.07
Full-threshold pure depression	1.07	(1.01, 1.13)	0.02	0.04
Full-threshold pure mania/hypomania	1	(0.89, 1.13)	0.97	0.91
Full-threshold mixed state	0.82	(0.33, 2.02)	0.67	0.69
Suicidal ideation	1.08	(0.99, 1.19)	0.09	0.11
Any comorbid disorder	1	(0.97, 1.04)	0.84	0.91
ADHD	1	(0.97, 1.03)	0.81	0.99
Any anxiety	1.02	(0.99, 1.05)	0.21	0.16
CD/ODD	1.01	(0.98, 1.04)	0.56	0.75
Substance use disorder ^d	0.99	(0.96, 1.03)	0.81	0.76
Percentage of weeks with psychiatric treatment in preceding six months				
Any psychosocial	0.99	(0.94, 1.04)	0.65	0.44
Inpatient/residential treatment	0.68	(0.29, 1.60)	0.38	0.39
Specialized psychosocial services	0.97	(0.89, 1.05)	0.43	0.36
Outpatient services	1.02	(0.96, 1.08)	0.63	0.83
Any psychotropic medication	1.03	(0.99, 1.07)	0.07	0.21
Antimanic anticonvulsants	1.04	(0.99, 1.10)	0.12	0.20
Lithium	1.02	(0.98, 1.06)	0.37	0.50
Second generation antipsychotics	1.02	(0.99, 1.05)	0.3	0.64
Antidepressants	1.06	(1.02, 1.10)	0.001	0.001
Stimulants	1.01	(0.98, 1.05)	0.5	0.99

^a unit of interpretation for odds ratio is 1 week

Abbreviations: ADHD: attention deficit-hyperactivity disorder; CD/ODD: conduct disorder/oppositional defiant disorder